Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 407 participants.
Also called NCT06005597
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 407 participants
- Sponsor
- Registry
-
NCT06005597
-
- Main results
- Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT06005597. Randomized; quadruple masking; primary purpose treatment. Start 2024-03-01 (actual); primary completion 2024-09-25 (actual). Results posted on 2025-10-08.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies
- Acronym
- TANDEM
- Condition
- Dyslipidemias
- Condition
- Hypercholesterolemia
- Condition
- Familial Hypercholesterolemia
- Condition
- ASCVD
- Condition
- High Cholesterol
- Intervention (Combination product)
- Combination Therapy
- Intervention (Drug)
- Monotherapy obicetrapib
- Intervention (Drug)
- Monotherapy ezetimibe
- Intervention (Other)
- Combination Therapy placebo
- Intervention (Other)
- Obicetrapib Placebo
- Intervention (Other)
- Ezetimibe Placebo
- Lead sponsor
- NewAmsterdam Pharma
Record details
- Record id
cardio:ct-nct06005597- Content hash
a9f17d3376ce16ab2a6c66714847ff0b868fc9ea76a34e11669f83f15d769bd1